The stakes of the question are high. Exercise-based rehabilitation is recommended as part of best-practice cancer care because regular physical activity can blunt the adverse effects of treatment, improve physical and psychological function, and enhance quality of life. Large-scale evidence cited by the researchers suggests that long-term exercise improves disease-free survival by 28 percent and overall survival by 37 percent in people with cancer. Yet survivors entering rehabilitation are typically far below recommended activity levels: previous studies report an average of just 12 minutes of moderate-to-vigorous activity per day, and half say they exercise fewer than two days a week.

Structured, supervised rehabilitation programs are seen as a promising first step toward changing those numbers, but keeping people active once the program finishes has proven difficult. Telerehabilitation — delivered through videoconferencing, wearable devices, and mobile applications — was developed to overcome practical barriers to attending in-person sessions, allowing participants to exercise safely at home while still receiving demonstration, instruction, monitoring, and expert guidance. Group-based cancer exercise telerehabilitation has been shown to be safe and feasible, although earlier work raised concerns that participants may find it harder to build the social connections that make in-person groups motivating.

In the TeleCaRe trial, participants in the experimental arm received an eight-week program of twice-weekly, 60-minute group exercise sessions supervised by a physiotherapist trained in cancer care. The sessions combined seated or standing aerobics, body-weight exercises such as squats, and equipment including resistance bands and free weights, all individually tailored. The program also incorporated information provision, self-monitoring through a Fitbit activity tracker, feedback, goal setting, an online information portal, and an individualized home exercise plan — a package of recognized behavior change techniques. Before starting, and again at discharge, participants discussed ongoing exercise options one on one with the physiotherapist.

To understand the medium-term impact, the researchers purposively sampled 17 trial participants — roughly half female, averaging 58 years old, with ages ranging from 21 to 80 — for semistructured interviews four months after their final session. Interviews were conducted by PhD-qualified physiotherapists not involved in delivering the program, audio-recorded, transcribed verbatim, and independently coded by two researchers using NVivo software. The team analyzed the data inductively within an interpretive description framework, refining a shared codebook through repeated discussion, and returned transcripts to participants to verify accuracy. Data collection ran from June 2022 to December 2023 across a large public health service spanning metropolitan Melbourne to regional Victoria.

The overarching theme that emerged was that telerehabilitation facilitated positive exercise intentions that persisted well beyond the program. Participants described the program as a lifeline that connected them with skilled, empathetic clinicians at a dark point in their recovery, empowering them through knowledge, opportunity, and connection. One participant with breast cancer recalled being weak, having lost her hair, and feeling awful, saying the program pulled her out of that period and calling such services a lifeline for people like her. Others articulated vivid long-term reasons for exercising, from coping better with chemotherapy to reducing the fear of recurrence.

For many, feeling the benefits of exercise during the program — less fatigue, a return to work — created a positive cycle that prompted them to seek further activity once it ended. Some returned to the gym, took up golf, lawn bowls, or swimming, or folded the program’s home exercises into their regular routines. Purposeful walking was the most common activity because it was convenient. Family members reinforced the momentum, sometimes exercising alongside participants or buying them equipment, and for some the program acted as a conduit back into community life, such as volunteering at a bowls club.

But acting on those intentions proved far harder in what participants called the new reality created by cancer. Comorbidities, ongoing treatment side effects such as pain and fatigue, and disrupted life circumstances limited many people’s ability to exercise, and some expressed guilt about not keeping up. Without the structure, accountability, and convenience of scheduled sessions, several described a disconnect between knowing they should exercise and actually doing so. COVID-19 added a double barrier: some participants contracted the infection and were physically unable to exercise, while others avoided community gyms and pools for fear of infection due to immunocompromise.

Previous exercise experience emerged as the strongest determinant of who kept moving. Survivors who had exercised before their diagnosis — swimming, running, gym training, regular walking — described those activities as goals to return to and appeared to bounce back quickly from setbacks, likely helped by higher self-efficacy. Those new to exercise held positive intentions but were less likely to act on them, often managing only incidental activity around the home or occasional walks. The researchers suggest this pattern fits the transtheoretical model of behavior change: telerehabilitation helps people move from contemplation into action, but the leap from action to maintenance is difficult once professional supervision disappears, and health setbacks can push people back toward contemplation even as their positive intent remains.

The authors conclude that telerehabilitation can be a valuable first step toward initiating exercise, but that many survivors — particularly those without previous exercise experience — need ongoing support afterward to convert good intentions into sustained behavior. In real-world clinical settings, resources rarely allow the years-long, phased support used in the landmark trial linking exercise to improved colon cancer survival, so the researchers point to flexible models such as physiotherapy navigators and community-based programs like LiveStrong at the YMCA or the Alberta Exercise Program to bridge the gap. The study has limitations: participants came from a motivated trial cohort who needed internet access, adherence to the program was low, and interviews were short, though no new themes emerged in the final transcripts. Even so, the message is clear — the webcam sessions plant the seed, but the hard work of keeping cancer survivors exercising begins when the screen goes dark.

Subject of Research: Cancer survivors' exercise behaviour after completing a group exercise telerehabilitation program

Article Title: A qualitative study of cancer survivors’ exercise behaviour 4 months after a telerehabilitation program

Article References: Dennett, A. M., Peiris, C. L., Rimayanti, M. U., Barton, C., Taylor, N. F., Harding, K. E., Tan, G., Ezzat, A., & Shields, N. (2026). A qualitative study of cancer survivors’ exercise behaviour 4 months after a telerehabilitation program. Supportive Care in Cancer, 34(10), Article 941. https://doi.org/10.1007/s00520-026-11016-y

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11016-y

Keywords: telerehabilitation, cancer survivors, exercise, behavior change, qualitative research, physiotherapy, cancer rehabilitation, telehealth, physical activity, survivorship, qualitative, cancer

In a Methods paper published in Frontiers in Virtual Reality, researchers led by Alex Fuentes-Raventos of the University of Barcelona describe NEOBIC-XR, a home-based extended reality exercise platform designed specifically for people with cancer, together with a multicenter evaluation framework being rolled out across three Spanish hospitals. The work is notable less for any single technological breakthrough than for its ambition to make virtual reality exercise clinically deployable, measurable, and reproducible — a combination that has largely eluded the field so far.

The platform runs on Meta Quest 3 standalone headsets and was built in Unity, combining the XR Interaction Toolkit, OpenXR plugins, and Meta’s interaction and movement software development kits. Voice content for the virtual trainers was generated with ElevenLabs and delivered as pre-produced audio assets. Participants move through three distinct virtual environments across the four-week program: a Roman Pantheon in week one, a green field in week two, and a beach in week three, with week four cycling back through the earlier scenes. Each environment is paired with a trainer avatar matched to the setting.

What distinguishes NEOBIC-XR from many exercise apps is its treatment of the body itself. Participants select an avatar — from a standard library or, optionally, a photorealistic avatar generated from a single frontal photograph of their own face. During exercise, the headset’s full-body tracking retargets the participant’s real movements onto that avatar in real time, so the virtual body mirrors what the person is actually doing. This creates conditions for embodiment — the psychological sense of owning and controlling a virtual body — which the researchers argue may matter particularly in oncology, where physical deconditioning often coexists with reduced confidence in movement.

The exercise sessions themselves are tightly structured. Each prescribed routine includes a five-minute embodiment and warm-up phase, four exercises drawn from upper-body tasks such as boxing and reaching, lower-body tasks such as squats and lateral movements, and a guided mixed-reality module, followed by a five-minute breathing routine. Each exercise begins with a tutorial containing two demonstrations at low, medium, and high intensity. The first demonstration is always performed by the trainer. The second is where the study’s most intriguing design question lives: in one condition, the trainer performs it while a visible duplicate of the participant’s own avatar — a body-double — watches from the side; in the other, the body-double performs the movement while the trainer continues delivering the same instructional audio.

That body-double manipulation is not decorative. Previous research, including work by co-author Mel Slater and colleagues, has shown that observing a virtual copy of oneself can influence behavior and even reduce persecutory thoughts in clinical populations. By counterbalancing which condition participants see first and alternating daily, the team can examine whether watching your own avatar perform an exercise changes how intensely you choose to train — a behavioral signal captured because intensity is selected immediately after tutorial exposure. The tutorial-format analysis will use a Bayesian modeling framework with hierarchical random effects to account for repeated day-level exposures within participants.

The evaluation study is a prospective, multicenter, non-randomized implementation study at Hospital Universitario Central de Asturias in Oviedo, Hospital General Universitario de Ciudad Real, and Hospital Universitario Infanta Leonor in Madrid. Adults with stage IV solid tumors who are clinically suitable for light-to-moderate exercise are enrolled in one of two pathways. Those who accept home XR use and can be accommodated within headset and onboarding capacity enter the XR-supported pathway, completing twelve prescribed sessions over four weeks. Everyone else — including those recruited outside the weekly XR-capacity window — receives written evidence-based physical activity recommendations and completes the same hospital-based questionnaires. The allocation ratio is roughly three written-recommendation participants for every XR participant, reflecting device availability and onboarding capacity rather than randomization.

The primary planned endpoint is the change in self-reported physical activity from baseline to three months, scored in MET-minutes per week using an IPAQ-style calculation that combines walking, moderate, and vigorous activity. Secondary endpoints span health-related quality of life, symptom burden, psychological distress, cognitive complaints, supportive care needs, and nutritional indicators. Within the XR pathway, first-day to last-day changes in Godin physical activity, exercise readiness, coping self-efficacy, and wellbeing are analyzed as proximal outcomes, alongside post-session ratings of presence, body ownership, agency, and tolerability symptoms such as nausea and dizziness.

Privacy shaped the architecture in unusual ways. The application stores no raw video or images; instead it records the joint positions and rotations of the retargeted avatar rig, producing derived kinematic trajectories that the researchers explicitly caution should not be interpreted as validated biomechanical measures without separate validation. Headsets are provisioned through study-managed accounts rather than personal Meta accounts, the app is distributed through a restricted Meta Horizon Store deployment, and participant-specific avatars remain locked behind unlock codes so that no one handling a shared device can browse someone else’s virtual self. Progress data are organized around local profiles rather than names, with structured JSON session logs and binary pose files linked to the study database through the local workflow.

Safety monitoring addresses both exercise and headset risks. Participants rate nausea, dizziness, headache, and muscle pain after every session, and serious adverse events judged related to the intervention trigger independent clinical review before any continuation decision. The team has also prespecified a traffic-light feasibility framework covering onboarding completion, home initiation, prescribed-session adherence, three-month retention, event-log completeness, pose-data completeness, and cybersickness-related discontinuation, with green thresholds set at levels such as at least 80 percent onboarding completion and a median of at least nine of twelve prescribed sessions completed. Recruitment, which began in 2026 under protocol NEOBIC-2025-01 approved by the Research Ethics Committee of the Principality of Asturias, is expected to run into 2027, targeting up to 40 XR participants and roughly 120 written-recommendation participants.

The authors are candid about the study’s limits. Because allocation is acceptance-based rather than randomized, between-pathway comparisons will be adjusted but pragmatic, vulnerable to confounding by motivation and technology acceptance. The intervention is deliberately multidimensional, so causal attribution to any single component — beyond the counterbalanced tutorial format — will remain out of reach. Still, if NEOBIC-XR can be delivered consistently across three hospitals, tolerated in repeated home use, and linked cleanly to clinic-based assessments, it would mark a shift for virtual reality in oncology: from a novelty demonstrated in small laboratory studies toward a structured rehabilitation strategy that can be evaluated, refined, and potentially woven into real cancer care pathways.

Subject of Research: A home-based extended reality exercise platform and multicenter evaluation framework for supportive oncology care

Article Title: NEOBIC-XR: a home-based extended reality exercise platform and multicenter evaluation framework for supportive oncology care

Article References: Fuentes-Raventos, A., Slater, M., Jimenez-Fonseca, P., Cruz-Castellanos, P., Ruiz-Eguino, A., Naveiras-Alba, C., Obispo, B., Cerda-Company, X., Menéndez-López, J., & Calderon, C. (2026). NEOBIC-XR: a home-based extended reality exercise platform and multicenter evaluation framework for supportive oncology care. Frontiers in Virtual Reality, 7, Article 1927617. https://doi.org/10.3389/frvir.2026.1927617

Image Credits: AI Generated

DOI: 10.3389/frvir.2026.1927617

Keywords: extended reality, virtual reality, exercise oncology, cancer rehabilitation, home-based exercise, metastatic cancer, embodiment, avatars, supportive care, implementation science, Meta Quest 3, digital health

The scale of the patient population makes the findings urgent. Breast cancer is the most commonly diagnosed malignancy among women in China, with roughly 420,000 new cases each year, and the five-year survival rate now exceeds 83 percent. That creates a rapidly growing cohort of long-term survivors whose recovery depends on structured rehabilitation, including upper-limb functional recovery, lymphedema management, psychosocial support, nutrition and exercise guidance, sexual and reproductive health, and body image restoration. Yet misconceptions remain pervasive, such as the belief that all arm movement must be avoided after surgery or that lymphedema is irreversible, and the study’s authors argue that timely, evidence-based education could meaningfully improve functional outcomes.

The research team, led by Siqi Wu of the Affiliated Hospital of Southwest Medical University and Jianxiong Wang of the Sichuan Clinical Research Center for Cancer, retrieved 1,428 videos using an account-free search mode between June and July 2026 to avoid algorithmic recommendation bias. After screening for duplicates, off-topic content, unidentifiable creators, and illegal online diagnosis, 450 valid videos remained, 150 per platform. Each was scored by six evaluators, three breast oncologists, two rehabilitation physicians, and one health communication researcher, using a three-dimensional system: content scientificity measured with a modified DISCERN scale, presentation quality with the Global Quality Scale, and source credibility with the JAMA scale. Inter-rater reliability during the calibration phase was strong, with an ICC of 0.84, and a post hoc power analysis exceeded 0.99.

The headline result is stark. The overall quality score across all 450 videos was 2.74 on a five-point scale, with a standard deviation of 0.85, and only 19.8 percent of videos reached the qualification threshold of 3.5, which denotes above-average quality. Sensitivity analyses using alternative cutoffs confirmed the conclusion was robust: 42.4 percent passed at a more lenient 3.0 threshold, while a strict 4.0 cutoff admitted just 6.7 percent. The weakest dimension was content scientificity, scoring 2.62, reflecting widespread problems such as oversimplified exercise prescriptions without contraindication warnings, failure to distinguish post-mastectomy from post-lumpectomy protocols, and missing lymphedema risk-reduction strategies.

Platform differences were significant and instructive. TikTok outperformed MicroBlog and Today’s Headline in overall quality, content scientificity, and source credibility, with effect sizes ranging from 0.11 to 0.16, and its pass rate of 30.7 percent was nearly double that of its competitors. But the regression analysis revealed the likely reason: TikTok’s quality advantage largely evaporated once creator composition was accounted for. Certified physicians made up 38.7 percent of TikTok creators in the sample, compared with just 15.3 percent on MicroBlog, a gap the authors attribute to TikTok’s stricter medical account certification and content audit systems. Even so, nearly 70 percent of TikTok videos still failed the quality threshold, suggesting platform governance alone is not enough.

The strongest predictor of quality was who made the video. A one-way ANOVA across four creator types produced one of the largest effect sizes in the study, with eta-squared values of 0.46 to 0.49. Certified physicians scored highest at 3.68, followed by rehabilitation nurses at 3.24, health institutions at 2.86, and ordinary users at 2.05, a gradient confirmed by Tukey post hoc tests. Ordinary users, who accounted for the largest share of creators on MicroBlog and Today’s Headline, produced content that averaged barely above the bottom of the scale. Notably, rehabilitation nurses, though underrepresented at about 11 percent of the sample, performed well, which the authors flag as an underutilized resource for patient education.

Equally revealing is what the videos did not cover. Treatment-related content dominated every platform, at 39 to 44 percent of videos, while sexual and reproductive rehabilitation was the scarcest theme at just 4.7 to 7.3 percent. That scarcity matters because fertility preservation, sexual function after endocrine therapy, and safe contraception are among the most common questions young patients ask their oncologists. The subgroup analysis also found that sexual and reproductive videos scored lowest of all six content domains, at 2.45, significantly below upper-limb and lymphedema content. The authors describe this as a utilitarian skew, in which click-attracting treatment topics crowd out the nuanced rehabilitation domains survivors actually need.

Perhaps the most provocative finding is a weak but statistically significant negative correlation between engagement and quality. Videos with more views, likes, and shares tended to score slightly lower on quality, with a Pearson correlation of minus 0.18 and a 95 percent confidence interval of minus 0.27 to minus 0.09. The authors are careful not to overstate this as a proven paradox, noting the effect is small and cross-sectional data cannot establish causation, but they outline plausible mechanisms: algorithms favor rapid, emotionally charged engagement over nuanced evidence-based material, and viewers may lack the expertise to distinguish accuracy from charisma. In oncology, where a cancer diagnosis carries emotional intensity and survivorship products carry commercial appeal, anecdotal content may hold particular sway.

The clinical consequences of low-quality content are not abstract. The authors warn that repeated exposure to inaccurate videos can foster unrealistic expectations or unnecessary fear, that incorrect exercise demonstrations may delay functional recovery or worsen lymphedema, and that patients may defer evidence-based therapy in favor of unproven alternatives promoted through engaging but misleading videos. The Cyberspace Administration of China reports that platforms remove roughly 714 items of illegal medical content daily, 62.3 percent involving exaggerated therapeutic claims and false advertising, a problem the study notes is especially acute in oncology.

The study has limitations worth noting. The sample was limited to 450 videos on a single disease entity on mainland Chinese platforms, YouTube was excluded because it is not broadly accessible in China, and relevance-based sampling cannot fully eliminate biases from proprietary ranking algorithms. The shortened DISCERN adaptation used here is study-specific and lacks independent external validation, and the cross-sectional design restricts all findings to associations rather than causal claims. Still, the practical recommendations are concrete: platforms should mandate qualification certification for medical rehabilitation creators and build tiered review systems, professional societies should develop authoritative video libraries, and algorithms should prioritize certified, high-quality content. In the meantime, patients are advised to trust videos from certified physicians and health institutions that cite guidelines, present balanced information, and avoid sensational claims, and to bring anything they see online to their own oncologist or rehabilitation specialist before acting on it.

Subject of Research: Quality evaluation of breast cancer rehabilitation videos on Chinese video-sharing platforms

Article Title: Three-dimensional evaluation and optimization of breast cancer rehabilitation science popularization videos on mainstream video platforms: a cross-sectional study in Mainland China

Article References: Wu, S., Chen, C., Chen, G., Wang, F., & Wang, J. (2026). Three-dimensional evaluation and optimization of breast cancer rehabilitation science popularization videos on mainstream video platforms: a cross-sectional study in Mainland China. Frontiers in Digital Health, 8, Article 1970196. https://doi.org/10.3389/fdgth.2026.1970196

Image Credits: AI Generated

DOI: 10.3389/fdgth.2026.1970196

Keywords: breast cancer, cancer rehabilitation, health misinformation, TikTok, social media, video quality, DISCERN, patient education, lymphedema, digital health, China, health communication

The research team, led by Yuan-Yuei Chen of Tri-Service General Hospital and National Defense Medical University in Taipei, together with colleagues including Chung-Ching Wang, drew on nationwide population-based databases in Taiwan to identify older workers who were diagnosed with cancer between 2004 and 2015. Taiwan’s comprehensive national health insurance system and linked administrative registries make it an unusually powerful setting for this kind of epidemiological work, allowing researchers to follow large numbers of patients over long periods with minimal loss to follow-up. The team used Cox proportional hazards models, a mainstay of survival analysis, to identify which sociodemographic, clinical, and work-related factors were associated with returning to work, and Kaplan–Meier analyses to compare long-term survival between survivors who returned to work and those who did not.

The statistical approach deserves a moment of explanation, because it shapes how the findings should be read. Cox proportional hazards models estimate the hazard—the instantaneous risk—of an event occurring at any given time, relative to a reference group, while adjusting for other variables in the model. In this study, the outcome of interest was the cause-specific hazard of returning to work during follow-up. Kaplan–Meier analyses, by contrast, produce survival curves that visually track the proportion of patients still alive over time, allowing researchers to compare mortality trajectories between groups. When the curves for two groups separate, that separation signals a difference in survival experience; when the separation widens over the follow-up period, it suggests the difference is growing.

What did the models reveal? Several factors were associated with a lower cause-specific hazard of returning to work among older survivors. Older age itself was a barrier, which is perhaps unsurprising given that advancing age brings both greater physical burdens from treatment and closer proximity to conventional retirement. Male sex was also linked to a lower hazard of returning to work, as were selected comorbidities—additional chronic conditions beyond the cancer itself. Receipt of chemotherapy or radiotherapy predicted a lower likelihood of returning to work, consistent with the well-documented fatigue, cognitive changes, and functional limitations that can accompany these treatments. Interestingly, higher income and engagement in physically demanding occupations were also associated with a reduced hazard of returning to work, a pattern that may reflect the physical toll of manual labor on older bodies recovering from cancer, as well as the possibility that higher-income workers face less financial pressure to resume employment quickly.

On the other side of the ledger, survivors diagnosed at earlier cancer stages had a higher cause-specific hazard of returning to work compared with those diagnosed at more advanced stages, and patients with colorectal, breast, or prostate cancer were more likely to return to work than the corresponding reference groups. These cancer types often carry relatively favorable prognoses and are associated with treatment regimens that may be less disabling than those for other malignancies. The stage effect is particularly intuitive: earlier-stage disease typically requires less aggressive therapy and leaves patients with better preserved functional capacity, making a return to the workplace more feasible.

The most eye-catching result, however, concerns survival. The researchers found that survival differed significantly between survivors who returned to work and those who did not, across all cancer stages. The separation of the Kaplan–Meier survival curves was more pronounced among patients with stage III or IV disease, suggesting that the association between returning to work and survival was especially visible in those with advanced cancer. Most importantly, in the Cox models, returning to work was independently associated with a reduced risk of all-cause mortality. In other words, even after accounting for other measurable factors, older survivors who went back to work died at a lower rate during follow-up than those who did not.

What could explain such an association? The authors are careful to frame returning to work as a marker that reflects both clinical recovery and broader social reintegration, rather than claiming that employment itself directly prolongs life. This distinction matters. Survivors well enough to work are, by definition, healthier on average than those who cannot work, a phenomenon epidemiologists call confounding by indication or, in this context, the healthy worker effect. Yet the relationship is unlikely to be purely one-directional. A substantial body of prior research links physical activity to lower mortality, including large analyses such as the PURE study spanning 130,000 people across 17 countries and meta-analyses of 71 prospective cohorts showing a dose-response relationship between physical activity and cancer mortality. Work, particularly for older adults, can provide structured activity, cognitive stimulation, social contact, and a sense of purpose—factors that other studies have tied to better health outcomes among cancer survivors and older adults generally.

The study also sits within a broader scientific conversation about aging and cancer. Researchers have described an aging-cancer cycle in which the biology of aging—cellular senescence, frailty, and declining tissue resilience—both increases cancer risk and complicates recovery, while cancer and its treatments can themselves accelerate aspects of aging. Comorbidity is a central player in this cycle: prior studies have shown that additional chronic conditions worsen mortality and quality of life among survivors of colorectal, breast, and other cancers. Depression, too, has been linked to elevated cancer mortality in recent meta-analyses. Against this backdrop, the new findings suggest that sustained work participation might be one tangible, measurable dimension of successful survivorship in older adults—one that occupational health services, rehabilitation programs, and employers could actively support rather than passively observe.

The practical implications are significant for societies with rapidly aging workforces. Taiwan, like many countries, is confronting the economic and social challenges of population aging, and policymakers there have explicitly promoted active aging and aging in place. If returning to work after cancer is a signal of resilience and reintegration, then survivorship-focused interventions—gradual return-to-work schedules, workplace accommodations, vocational rehabilitation, and coordination between oncology teams and occupational physicians—could help more older survivors achieve it. Prior studies of interdisciplinary rehabilitation programs in breast and prostate cancer survivors have shown that structured support can improve occupational reintegration, and research on barriers to return-to-work has repeatedly identified employer attitudes, symptom burden, and lack of guidance as modifiable obstacles. The Taiwanese study’s authors conclude that survivors who returned to work experienced more favorable survival outcomes, highlighting the importance of supportive, survivorship-focused interventions that facilitate sustained work participation among older adults. As the global population of older cancer survivors continues to grow, the question is shifting from whether elderly patients can return to work to how medicine and society can help them do so—and whether doing so might, in turn, help them live longer, more engaged lives.

Subject of Research: Return to work and long-term survival among elderly cancer survivors

Article Title: Return to work in elderly population with cancer

Article References: Chen, Y.-Y., Chen, Y.-J., Wu, W.-T., & Wang, C.-C. (2026). Return to work in elderly population with cancer. Supportive Care in Cancer, 34(10), Article 960. https://doi.org/10.1007/s00520-026-11201-z

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11201-z

Keywords: return to work, cancer survivors, elderly, survival analysis, Cox proportional hazards, Kaplan–Meier, Taiwan, comorbidity, occupational health, cancer rehabilitation, gerontology, survivorship

The study matters because chronic cancer-related pain is both common and chronically under-recognized. Previous research has estimated that chronic pain affects between 28 and 47 percent of cancer survivors, and US population-based data have shown a prevalence of 31 percent among people with a cancer history compared with 16 percent among those without one. In a US survey of more than 4,500 survivors, 36 percent reported chronic pain, and nearly half of those were categorized as having high-impact chronic pain. Yet routine assessment of pain characteristics is not standard practice in many oncology settings, which means the patients who most need intensive, interdisciplinary support can slip through the cracks. The Danish team set out to test whether a brief, validated questionnaire could systematically separate survivors whose pain is a nuisance from those whose pain is life-altering.

The GCPS-R is a six-item self-administered instrument that classifies chronic pain, defined as pain on most days or every day during the past three months, into hierarchical grades: mild chronic pain, bothersome chronic pain, and high-impact chronic pain. High-impact chronic pain is defined as pain persisting for at least three months that limits life activities or work on most days or every day. Among participants with chronic pain who do not meet that threshold, the scale uses a three-item Pain, Enjoyment and General Activities score with a cut-off of 12 or higher to distinguish bothersome from mild pain. Because the tool was originally developed for chronic non-cancer pain, its application to a cancer population is relatively novel, and the researchers wanted to know whether it could carve out clinically meaningful subgroups among survivors.

The cohort consisted of adults attending REHPA’s structured rehabilitation courses between March 2022 and February 2025. These courses follow a distinctive format: an initial five-day residential stay, seven to ten weeks at home, and a final two-day follow-up. Before arrival, participants completed a routine screening questionnaire covering quality of life, psychological distress, fatigue, sleep, and pain. Those meeting predefined pain criteria, such as average pain intensity of at least 4 on a 0-to-10 numeric scale over the past two days, or pain interfering substantially with daily activities, were invited to complete a supplementary pain-specific module. Of 877 course participants, 375 met the pain criteria, and 300 completed the supplementary module. After excluding respondents with incomplete data or without chronic pain by the GCPS-R definition, the final analytical sample comprised 270 survivors with chronic pain.

The underlying diagnoses reflected the realities of rehabilitation referrals: 58 percent had breast cancer, 9 percent gastrointestinal cancer, and 9 percent hematological cancers, mainly multiple myeloma, with the remainder spread across other diagnoses. When the GCPS-R was applied, 13 percent were classified as having mild chronic pain, 26 percent bothersome chronic pain, and 61 percent high-impact chronic pain. More than half of the entire cohort, 54.8 percent, reported pain lasting more than a year, and long duration was most common in the high-impact group, where 62.7 percent had lived with pain for over a year, compared with 44.3 percent of the bothersome group and 38.2 percent of the mild group, a statistically significant difference.

The gradient across grades was striking and internally consistent. Survivors with high-impact pain reported significantly higher pain intensity and pain-related disability, more widespread pain, higher depression scores, and lower self-rated health and quality of life than those in the bothersome and mild groups, with all comparisons reaching statistical significance. Mean pain intensity corresponded to moderate-to-severe levels in the high-impact group, moderate levels in the bothersome group, and low levels in the mild group. Pain catastrophizing, measured with a single validated item from the Pain Catastrophizing Scale asking whether pain feels terrible and never-ending, and disability scores on the Pain Disability Index were also significantly elevated in the high-impact and bothersome groups relative to the mild group. Notably, the three groups were similar in age, sex, marital status, education, and health behaviors, suggesting that the classification was capturing differences in pain impact rather than demographic confounding.

Perhaps the most provocative part of the study was its exploratory comparison with non-cancer pain patients. The researchers matched 166 cancer survivors with high-impact chronic pain to 498 patients with non-cancer high-impact chronic pain drawn from the Danish PainData Registry, using stratified random sampling in a 1-to-3 ratio within ten-year age bands and matching on age and sex. The non-cancer patients had typically endured pain far longer: among those with available data, 94.2 percent had pain lasting more than a year, with a median duration of 7.6 years and a mean of 11.1 years. Despite meeting the same impact criteria, the two groups looked different on several dimensions.

The non-cancer group reported significantly higher pain intensity, greater pain-related disability, more depressive symptoms, more pain catastrophizing, larger pain distribution, and lower self-rated health, with effect sizes ranging from small to large, including a large difference in disability. Anxiety scores, however, were statistically indistinguishable between the groups. The most intriguing finding concerned widespread pain, defined by the American College of Rheumatology 1990 criteria as pain on both sides of the body, above and below the waist, and in the axial skeleton. Although the non-cancer patients reported more pain areas overall, cancer survivors were at least as likely to meet the widespread pain criteria, with roughly two-thirds of the high-impact cancer group fulfilling them. The authors suggest this pattern may reflect the spatial signature of treatment-related pain: chemotherapy-induced peripheral neuropathy often affects both upper and lower extremities, and hormonal therapies such as aromatase inhibitors and surgical late effects are associated with persistent, diffuse pain.

These differences also map onto evolving diagnostic frameworks. Under the ICD-11 classification, chronic cancer-related pain is categorized as chronic secondary pain, attributable to a known disease or its treatment, whereas many non-cancer pain patients fall under chronic primary pain, where pain itself is the principal problem and often lacks a clear biomedical cause. The authors argue that such typological distinctions may shape how patients interpret symptoms and cope with them, and that high-impact pain is a heterogeneous construct whose clinical presentation and drivers differ across populations. In practical terms, the findings suggest that cancer survivors with high-impact pain may need tailored, interdisciplinary interventions that go beyond standard biomedical approaches, and that access to cancer-specific pain expertise deserves strengthening.

The study has clear limitations that temper its conclusions. It drew on a selected population of survivors who actively applied for rehabilitation at a single center, potentially biasing the sample toward more resourceful or motivated individuals, and women were heavily overrepresented. Detailed clinical variables such as disease stage, time since diagnosis, and specific treatments were not systematically available, pain was self-reported as cancer-related without clinical verification, and some participants with pain lasting less than three months were nonetheless classified as having chronic pain. Still, the prospective design, relatively large sample, low missing-data rates, and the well-characterized matched comparison group lend the findings weight. The core message is hard to ignore: when cancer survivors report pain, more than half may be living with pain severe enough to disrupt daily life, and a six-item questionnaire can identify them. Systematic assessment of pain impact, not just its presence, could become a simple, powerful step toward getting the right survivors the right care.

Subject of Research: Classification of high-impact chronic cancer-related pain among cancer survivors using the Graded Chronic Pain Scale-Revised

Article Title: Identification of high-impact chronic pain among cancer survivors: a cross-sectional study using the Graded Chronic Pain Scale framework

Article References: Jespersen, J. R., Vaegter, H. B., Elnegaard, C. M., & Jarlbaek, L. (2026). Identification of high-impact chronic pain among cancer survivors: a cross-sectional study using the Graded Chronic Pain Scale framework. Supportive Care in Cancer, 34(10), Article 961. https://doi.org/10.1007/s00520-026-11190-z

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11190-z

Keywords: cancer survivors, chronic pain, high-impact chronic pain, Graded Chronic Pain Scale-Revised, pain classification, cancer rehabilitation, pain disability, psychological distress, widespread pain, ICD-11, interdisciplinary pain care, supportive care

The correspondence, published on 16 September 2026, responds directly to the CaRe feasibility study, a head and neck cancer rehabilitation trial published earlier in the same journal in June 2026 by Sheill and colleagues. Feasibility studies occupy a crucial niche in clinical research. They test whether a trial can actually be done: whether patients will enrol, whether clinicians can deliver the intervention consistently, whether outcome measures are tolerable and interpretable, and whether attrition stays within acceptable limits. The CaRe study did exactly this work for a structured rehabilitation programme in head and neck cancer, laying the groundwork that larger definitive trials require.

Yet Abou-Bakr and Hassanein contend that a trial can pass every feasibility benchmark and still fail to answer the questions that matter most to patients, if it treats all head and neck cancer survivors as a single homogeneous group. Their central argument is that lymphoedema is not a minor comorbidity to be averaged out in randomisation; it is a distinct clinical entity that changes what rehabilitation should look like, what outcomes are realistic, and how success should be measured. Pooling patients with and without lymphoedema, they suggest, risks diluting treatment effects and obscuring the very signals that a definitive trial is designed to detect.

The clinical case for stratification rests on a growing body of evidence about what head and neck lymphoedema actually does to patients. A 2026 systematic review by Gaitatzis and colleagues in the Journal of Cancer Survivorship examined patient-reported outcome measures and physical function following head and neck lymphoedema and documented the breadth of its impact. Unlike limb lymphoedema, which is visible and relatively straightforward to measure with circumference or volume techniques, lymphoedema in the head and neck region affects structures that govern speech, swallowing, breathing, and appearance. Internal lymphoedema, involving the pharynx and larynx, can be invisible from the outside while profoundly impairing function.

The burden extends well beyond physical symptoms. Research by Starmer and colleagues, published in Supportive Care in Cancer in 2023, captured the patient perspective on head and neck lymphoedema and quality of life, revealing how swelling reshapes identity, social interaction, and emotional wellbeing. A 2024 study by Arends and colleagues in the journal Cancers added further weight, showing that lymphoedema and trismus, the restriction of jaw opening that frequently accompanies treatment, have a measurable impact on body image and quality of life after head and neck cancer. For a population already coping with disfigurement, altered speech, and compromised swallowing, lymphoedema compounds the challenge of returning to a recognisable life.

Against this backdrop, the evidence base for treating head and neck lymphoedema remains strikingly thin. A 2025 systematic review by de-la-Cruz-Fernández and colleagues in Supportive Care in Cancer assessed randomised controlled trials of physical therapy interventions for lymphoedema management in this population and found the available trials limited in number and scope. This scarcity is precisely why feasibility work such as the CaRe study matters, and equally why the field cannot afford to design its definitive trials carelessly. If the few large trials that eventually emerge fail to account for lymphoedema status, an entire generation of rehabilitation evidence may be built on foundations too heterogeneous to support firm conclusions.

The argument for lymphoedema-stratified trial design has technical dimensions that go beyond simple subgroup analysis. Stratification in randomised trials means that patients are grouped by a key prognostic characteristic before randomisation, ensuring that treatment and control arms are balanced for that characteristic. In the context of head and neck cancer rehabilitation, stratifying by lymphoedema presence, severity, or type, external versus internal, would allow investigators to estimate whether rehabilitation produces different benefits in patients whose lymphatic systems have been compromised. It would also permit pre-specified subgroup analyses that are powered and planned from the outset, rather than the underpowered post hoc explorations that have historically plagued rehabilitation research.

Measurement is another pillar of the argument. Trials that ignore lymphoedema may choose outcome instruments that are insensitive to the changes that matter most to affected patients. The systematic review by Gaitatzis and colleagues highlighted the state of patient-reported outcome measures in this space, and the correspondence implicitly raises the question of whether generic quality-of-life instruments can capture the specific distress of facial and neck swelling, or whether lymphoedema-specific measures should be embedded in trial design. A rehabilitation programme might improve general physical function while leaving a patient’s lymphoedema-related body image concerns untouched, a result that a poorly designed trial would misread as partial success rather than a targeted failure.

The broader context of head and neck cancer survivorship strengthens the case further. Studies of rehabilitation needs, including work by Karampela and colleagues published in Frontiers in Oncology in 2021, have documented gaps between what patients require and what services deliver, while a 2025 systematic review by Bernstein and colleagues catalogued the social impacts of treatment and rehabilitation in this population. Head and neck cancer survivors face some of the highest rates of depression, social withdrawal, and functional impairment in oncology, and rehabilitation is the discipline charged with restoring what treatment takes away. Designing rehabilitation trials that reflect the true clinical heterogeneity of the population is therefore not a methodological nicety; it is a prerequisite for evidence that translates into meaningful care.

Abou-Bakr and Hassanein’s correspondence, written without specific funding and with no declared competing interests, functions as a call to action for trialists in supportive and rehabilitative cancer care. The message is that the field has demonstrated it can run rehabilitation studies in head and neck cancer; the CaRe feasibility study and its predecessors have answered the operational questions. The next step demands more ambition: definitive trials in which lymphoedema is not an afterthought but a design principle, with stratified randomisation, lymphoedema-sensitive outcome measures, and analyses planned to reveal which patients benefit most from which interventions. For the growing population of head and neck cancer survivors living with swelling that affects how they speak, swallow, and see themselves in the mirror, the difference between a generic rehabilitation trial and a lymphoedema-stratified one could ultimately determine whether the evidence that guides their care is sharp enough to help them.

Subject of Research: Lymphoedema-stratified rehabilitation trial design in head and neck cancer survivorship

Article Title: Beyond feasibility: the case for lymphoedema-stratified rehabilitation trials in head and neck cancer

Article References: Abou-Bakr, A., & Hassanein, F. E. A. (2026). Beyond feasibility: the case for lymphoedema-stratified rehabilitation trials in head and neck cancer. Supportive Care in Cancer, 34(10), Article 977. https://doi.org/10.1007/s00520-026-11222-8

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11222-8

Keywords: head and neck cancer, lymphoedema, cancer rehabilitation, clinical trial design, stratification, feasibility study, quality of life, supportive care, physical therapy, trismus, patient-reported outcomes, cancer survivorship

The study, conducted at the Azienda USL–IRCCS of Reggio Emilia and published in Supportive Care in Cancer, evaluated the UNAMANO project, a social-healthcare pathway developed in 2018 to address the work-related difficulties of cancer survivors living in the Province of Reggio Emilia. Rather than testing effectiveness, the researchers set out to answer a more fundamental question: is such a complex, individualized intervention actually deliverable in a real-world healthcare setting? Feasibility was measured through a series of concrete metrics, including the percentage of eligible patients invited to participate, the proportion who accepted, dropout rates, adherence to the intervention, satisfaction with the support received, and ultimately the rate of return to work.

The clinical rationale for the work is sobering. In Italy, 436,000 new cancer diagnoses were recorded in 2022, and breast cancer accounted for 13.2 percent of incident cases, with nearly half occurring in people of working age. Cancer survivors are 1.4 times more likely to be unemployed than healthy individuals, and while 73 percent of long-term survivors employed at diagnosis eventually return to work, that figure falls to 65 percent six years after diagnosis. Among breast cancer survivors specifically, return-to-work rates range from 56 to 88 percent. The obstacles are both physical and organizational: upper limb disability and lymphedema can make physically demanding tasks impossible, cancer-related fatigue and cognitive problems often prolong absences, and strenuous postures or shift work have been linked to a higher risk of never returning to work within two years of diagnosis.

Compounding these biological challenges is a communication gap within healthcare itself. Patients frequently hesitate to raise employment concerns with their oncologists, and clinicians tend to address work issues only when patients bring them up first. Yet survivors often need concrete information about employment rights, practical workplace accommodations, and emotional support as they navigate the transition from patient back to worker. Previous research has shown that multidisciplinary interventions combining vocational counseling, patient education, and physical exercise can enhance return to work compared with standard care, but these approaches must be adapted to local contexts and individual needs to be effective, a principle that shaped the design of the UNAMANO pathway.

The intervention itself is deliberately flexible. Participants can receive one or more of three types of support: information, occupational therapy, and social support, all provided free of charge. Occupational therapy, the most frequently delivered module, encompasses the collection of work needs, goal setting, and the definition of coping strategies agreed upon with the participant. The pathway also integrates with the broader supportive care services of the Reggio Emilia hospital network, including psycho-oncology, physical therapy, and nutritional support, allowing healthcare professionals to discuss cases and coordinate care across disciplines. Work-related difficulties were systematically categorized using the Core Set-VR-Onco, a checklist based on the World Health Organization’s International Classification of Functioning, Disability and Health that was recently adapted and validated for cancer survivors in the region.

Recruitment proved to be the study’s most instructive challenge. Of 85 working-age individuals with breast cancer recruited from a concurrent observational study, 32, or 37.6 percent, met the eligibility criteria and were invited to participate; half of those accepted and signed informed consent. Notably, no eligible patient who was merely referred to the UNAMANO project during a post-surgical educational session, without the deeper engagement of the observational study, ever contacted the service. The researchers interpret this as evidence that discussing work-related difficulties with healthcare professionals is itself a facilitating factor, and that passive referral may not be enough to connect patients with the support they need. Recruitment peaked at four months after surgery, while most work difficulties and study proposals emerged between seven and thirteen months post-surgery, suggesting that patients may be more receptive to vocational support once the acute phase of clinical recovery has passed.

Once enrolled, participants largely stayed the course. The overall dropout rate was 25 percent, with the highest single loss, 12.5 percent, occurring at baseline: one participant withdrew because of high emotional distress, and another declined to commit to another year of appointments after completing the observational study’s follow-up. Adherence to the intervention remained above 90 percent at the one- and three-month assessments, dipped to 75 percent at six months, and returned to nearly 90 percent at twelve months. Assessment appointments, initially conducted in person and averaging roughly 53 minutes at baseline, shifted steadily toward remote delivery at participants’ request, with nine of the eleven final participants opting for telephone follow-up by the study’s end, a pattern the authors note mirrors findings from a Scottish feasibility study where telephone appointments dominated.

The outcomes were encouraging. By the twelve-month assessment, ten of the eleven remaining participants had achieved work reintegration, whether by returning to their previous workplace or joining a different employer, and the same near-universal rate was observed at six months. Every participant assessed at the final timepoint reported being satisfied with the intervention, a result the researchers attribute in part to the continuous twelve-month follow-up, which continued regardless of employment status even after participants had returned to work. Interestingly, four participants were offered the option of organizing part of the intervention directly at their workplace, but none accepted, and some participants completed their intervention modules before the study formally ended because their needs had already been met, prompting the authors to suggest that future programs could define clearer criteria for concluding support.

The study population itself offers a portrait of the modern working cancer patient: all participants were women with a mean age of 50.7 years, most were private-sector employees with permanent contracts, and roughly two-thirds described their jobs as psychologically demanding while half reported physically demanding work. The authors are candid about the limitations. Recruitment drew exclusively from a cohort of patients who had undergone lymph node surgery and attended an educational session, excluding those with different prognoses and raising concerns about equitable access, particularly since only about 60 percent of eligible patients attend such sessions. The target sample size was not reached, and social desirability bias cannot be excluded, since the occupational therapist who delivered the intervention also conducted the follow-up assessments.

Nevertheless, the findings carry significant weight for the design of future cancer rehabilitation programs. The researchers argue that assessing work-related difficulties and delivering supportive interventions may be more appropriate several months after surgery rather than in the immediate postoperative period, when patients are focused on clinical recovery and prognosis. They call for further investigation of the occupational therapist’s role, which emerged as the backbone of the UNAMANO pathway, and for rigorous effectiveness trials of integrated approaches combining vocational interventions, physical exercise, and psychological support, not only for breast cancer but across cancer types. As survival rates continue to climb, the question is shifting from whether patients will live to how well they will live, and for millions of survivors, a meaningful answer must include the dignity and financial security of a working life restored.

Subject of Research: Feasibility of a multidisciplinary intervention to support return to work in working-age breast cancer patients

Article Title: A multidisciplinary intervention to support return to work of individuals with breast cancer: a prospective feasibility study

Article References: Paltrinieri, S., Braglia, L., Bravi, F., Fugazzaro, S., & Costi, S. (2026). A multidisciplinary intervention to support return to work of individuals with breast cancer: a prospective feasibility study. Supportive Care in Cancer, 34(10), Article 979. https://doi.org/10.1007/s00520-026-11198-5

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11198-5

Keywords: breast cancer, cancer survivors, return to work, occupational therapy, vocational rehabilitation, feasibility study, cancer rehabilitation, UNAMANO project, multidisciplinary intervention, supportive care, work-related difficulties, ICF framework

The research team, led by Zhengxin Hui and Liang Li, who contributed equally to the work, and supervised by Yinping Zhang and Tonggang Fan, conducted systematic searches of PubMed, Web of Science, Embase and the Cochrane Library up to August 2026. From these searches they assembled an unusually large evidence base: 149 randomized controlled trials encompassing 13,004 patients with cancer. Randomized controlled trials are considered the gold standard for estimating causal effects because participants are assigned by chance to an intervention or a comparison group, which balances out the confounding factors that plague observational studies. Pooling 149 of them therefore offers one of the most comprehensive pictures to date of how different exercise prescriptions perform in cancer populations.

What makes this study methodologically distinctive is its dual approach. First, the authors performed a Bayesian network meta-analysis, a technique that goes beyond traditional pairwise meta-analysis by allowing every intervention to be compared with every other intervention, both directly, when trials tested two modalities against each other, and indirectly, when trials linked them through a common comparator such as usual care. This creates a network of evidence in which the relative standing of each exercise type can be estimated even if no single trial ever compared them all in one experiment. To rank the interventions, the team used the surface under the cumulative ranking curve, or SUCRA, a metric that runs from zero to 100 percent and expresses the probability that a given treatment ranks highest among all the options evaluated.

The SUCRA rankings produced a clear shortlist of top performers. Qigong and Tai Chi, the slow, flowing mind-body practices rooted in traditional Chinese movement culture, emerged among the highest-ranked interventions, alongside high-intensity interval training, better known as HIIT, and combined aerobic and resistance training. The prominence of Qigong and Tai Chi is striking because these are low-impact, low-load practices that many patients with advanced disease, fatigue or treatment-related limitations can actually perform. Their high ranking suggests that the gentle, rhythmic, breath-coordinated character of these practices may deliver quality-of-life benefits that rival far more strenuous regimens, a finding with immediate relevance for patients who cannot tolerate intense exercise.

HIIT, by contrast, represents the opposite end of the intensity spectrum. It alternates short bursts of near-maximal effort with recovery periods, and it has attracted growing interest in exercise oncology because it achieves substantial cardiovascular and muscular stimulus in a compressed amount of time. Combined aerobic and resistance training, the third top-ranked modality, blends endurance work such as walking or cycling with strength work using weights or bodyweight resistance. The convergence of these three very different modalities at the top of the rankings underscores an important point: there is no single best exercise for quality of life in cancer care, but rather several distinct pathways, each with its own dose requirements, that appear to lead to similar destinations.

The second analytical pillar of the study was a network dose-response meta-analysis, abbreviated MBNMA in the paper, which models how the effect of an intervention changes as a function of its dose. The researchers quantified exercise dose using MET-minutes per week, a standard unit in exercise science in which one metabolic equivalent, or MET, represents the energy cost of resting quietly, and brisk physical activity typically registers at three to eight METs. A person walking briskly for five hours a week at roughly four METs would accumulate about 1,200 MET-minutes. Rather than assuming that more exercise is always better, the team fitted an Emax model, a nonlinear function borrowed from pharmacology that describes how a response rises with dose, approaches a maximum, and then plateaus.

The dose-response modelling delivered one of the study’s headline findings: the association between exercise dose and quality of life is nonlinear, with the model-estimated overall effect peaking at approximately 2,000 MET-minutes per week. Below that threshold, additional exercise appears to buy meaningful gains in wellbeing; beyond it, the model suggests diminishing returns. This kind of plateau is biologically plausible. Quality of life is constrained not only by physical capacity but by fatigue, psychological distress, sleep and social functioning, and once exercise has extracted the improvements it can deliver in these domains, pushing the dose higher may add strain without adding benefit. The finding echoes the shape of dose-response curves reported in other exercise-oncology research and gives clinicians a concrete numerical anchor for prescription.

Crucially, the peak dose was not the same for every modality. The model-estimated maximum effect for Qigong and Tai Chi occurred at a much lower dose, around 750 MET-minutes per week, which corresponds to only a few hours of gentle practice spread across the week. HIIT reached its model-estimated maximum at about 800 MET-minutes per week, consistent with the idea that high-intensity work delivers its stimulus efficiently. Combined aerobic and resistance training required the largest dose, with the model placing its maximum effect at roughly 2,000 MET-minutes per week, in line with the overall peak. In practical terms, a patient who enjoys and tolerates combined training may need to invest considerably more weekly activity to reach the modelled optimum, whereas a patient drawn to mind-body practice or interval work may achieve comparable modelled benefit at a fraction of that volume.

The authors are careful to frame these estimates as model-derived values that require prospective validation. Network meta-analysis and dose-response modelling are observational in the sense that they reanalyse existing trial data rather than testing prescriptions in new patients, and the Emax parameters depend on the doses represented in the included trials, which were not designed with a common dose grid in mind. Heterogeneity across cancer types, treatment stages, outcome instruments and intervention durations can all influence the pooled estimates, and the Bayesian framework makes its assumptions explicit but does not eliminate them. The study was funded by the Shanghai Oriental Talent Program Youth Project, and the authors declare no competing interests. The work is published open access, making the full analysis available to clinicians and researchers worldwide.

Even with those caveats, the study arrives at a moment when exercise is being formally integrated into cancer care pathways in many health systems, and it offers something those pathways have lacked: a comparative, quantified map of the options. For a patient beginning rehabilitation after chemotherapy, the findings suggest that a low-dose Qigong or Tai Chi routine may be an evidence-supported starting point, particularly when fatigue or deconditioning makes vigorous activity unappealing. For a fitter patient, HIIT or a combined aerobic and resistance program, dosed with the modelled peaks in mind, represents an alternative route to the same goal. What the analysis ultimately reinforces is that in exercise oncology, as in pharmacology, the prescription matters, the dose matters, and the best regimen is the one that matches the right modality to the right patient at the right intensity.

Subject of Research: Comparative effectiveness and dose-response of exercise interventions on quality of life in patients with cancer

Article Title: Optimizing exercise regimens for quality of life in patients with cancer: a network meta-analysis and dose–response study

Article References: Hui, Z., Li, L., Zhang, Y., & Fan, T. (2026). Optimizing exercise regimens for quality of life in patients with cancer: a network meta-analysis and dose–response study. BMC Cancer. https://doi.org/10.1186/s12885-026-17109-5

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17109-5

Keywords: cancer rehabilitation, exercise oncology, quality of life, network meta-analysis, dose-response, HIIT, Tai Chi, Qigong, aerobic training, resistance training, randomized controlled trials, SUCRA

The study, published in Holistic Integrative Oncology, enrolled 108 women between November 2022 and June 2023, of whom 98 completed the protocol, with 49 assigned to each arm. To be eligible, patients had to be between 18 and 65 years old, have unilateral upper-extremity lymphedema defined as a circumference difference of at least two centimeters between the affected and healthy limbs, and have finished adjuvant chemotherapy and radiotherapy. Those with serious cardiopulmonary, orthopedic, neurologic, cognitive, or emotional disorders, metastatic cancer, or active infection were excluded. Randomization was performed by a blinded researcher using computer-generated numbers, with allocation concealed in sealed, sequentially numbered opaque envelopes, and all outcome assessments were carried out by an assessor who did not know which group each patient belonged to.

The intervention itself was a graduated, eight-week program delivered twice a day, five days a week, in small supervised groups of five to six women. Each session lasted roughly twenty minutes, split evenly between aerobic-style mobility work and resistance exercise using adjustable dumbbells. The resistance component included seated rows, latissimus dorsi pulldowns, one-arm bent-over rows, biceps curls, bench presses, and triceps extensions, performed in two to three sets of eight to twelve repetitions. Crucially, the load was individualized: each participant underwent a one-repetition maximum test before starting, then trained at just 20 percent of that maximum for the first two weeks, rising to 60 percent in weeks five and six and 80 percent in the final fortnight, with the absolute weight capped at 2.5 kilograms. Throughout, participants kept compression bandages on, in line with guideline recommendations that compression be worn during moderate resistance exercise at home.

The control group received standard complex decongestive physiotherapy, the internationally recognized gold standard that combines manual lymphatic drainage, compression therapy, skin care, and functional exercise. In the first month, these patients attended hospital-based sessions once a day, five days a week; in the second month, they self-managed at home with twenty minutes of aerobic exercise twice daily. What they did not receive was the progressive resistance component, allowing the trial to isolate the added value of weight training on top of conventional care. Adherence was tracked through electronic logs completed by physiotherapists, with high adherence defined as attending at least 80 percent of offered sessions, and participants reported their exercise through an internet follow-up platform with online access to therapists.

The primary outcome was limb circumference, measured at standardized anatomical landmarks: the midpoint of the ulnar styloid process, points 10, 20, 30, and 40 centimeters above it, and the axillary root. After eight weeks, the mean difference in circumference between the healthy and affected sides fell significantly in the intervention group, while the control group showed no significant change. The effect was most pronounced at the 10-centimeter and 20-centimeter marks above the elbow crease, where the between-group differences reached statistical significance. Upper limb function, assessed with the Disabilities of the Arm, Shoulder and Hand questionnaire and digital goniometer measurements of shoulder range of motion, did not differ significantly between the groups, a result the authors attribute at least in part to the modest sample size.

Perhaps the most intriguing finding concerned the mind rather than the muscle. Baseline anxiety, measured with the seven-item Generalized Anxiety Disorder scale, was comparable between groups, but after two months the intervention group’s anxiety scores were significantly lower than those of the controls. Depression, measured with the nine-item Patient Health Questionnaire, and quality of life, measured with the 36-item Functional Assessment of Cancer Therapy-Breast instrument, showed no statistically significant differences, although quality-of-life scores trended slightly higher in the exercising group. The authors suggest the absence of significance on those secondary measures may reflect the short eight-week window, which may simply have been too brief for broader psychosocial benefits to register on validated scales.

The physiological rationale for why lifting light weights could drain a swollen arm rests on what the researchers describe as a dual pump mechanism. Lymphatic vessels normally move fluid through their own rhythmic, autonomic contractions, but in lymphedema, valve insufficiency and damage to the muscular wall of the lymphatics impair this intrinsic transport, leaving skeletal muscle contraction as the dominant force pushing lymph back toward the torso. Breast cancer surgery damages chest wall and upper limb muscles, and scar tissue contracture can stiffen the shoulder, weakening this so-called muscle pump. Resistance training rebuilds that pump, while the flexion and extension of the joints themselves stimulates lymph nodes and vessels in what the authors call a joint pump, together promoting lymphatic return and reducing fluid accumulation. Compression garments worn during exercise provide the external pressure gradient that keeps newly mobilized fluid from pooling again distally.

The anxiety finding has a plausible neuroendocrine explanation as well. Anxiety is thought to arise, at least in part, from dysregulation of the hypothalamic-pituitary-adrenal axis, the body’s central stress system, producing hypervigilance and sympathetic overdrive. Resistance exercise acutely elevates testosterone and cortisol concentrations and, over weeks of training, appears to modulate this axis, offering a mechanistic bridge between mechanical work in the gym and measurable relief of psychological distress. The authors note that prior trials, including one in breast cancer patients receiving chemotherapy, failed to detect an anxiolytic effect of resistance training, and they caution that differences in populations and assessment tools mean the psychological benefits in lymphedema patients still require confirmation in larger studies.

The trial’s authors are candid about its limitations. The sample was small, the follow-up was short, and the study was conducted at a single center, all of which constrain the generalizability of the results and may explain why functional status and quality of life did not reach significance. Missing data were excluded from analysis, and the statistical thresholds were conventional, with significance set at P less than 0.05. Still, the direction of the findings aligns with a growing body of evidence: systematic reviews and meta-analyses have concluded that resistance exercise is safe for lymphedema patients, improves muscle strength and physical function, and does not trigger or worsen the condition, overturning decades of advice that told survivors to baby their affected arms.

The broader implications extend beyond swelling. Epidemiological research has linked resistance training at least once a week to a 33 percent reduction in mortality risk among breast cancer survivors, and earlier work by members of this research community showed that a twice-weekly, slowly progressive weight training program halved the incidence of clinical events requiring medical care for lymphedema, even if it did not reduce arm swelling itself. What the Tianjin trial adds is the suggestion that, when paired with compression, supervised progressive loading may actually reverse some of the circumference difference that defines the disease. For a condition long considered incurable and managed mainly through meticulous maintenance, the message to survivors is quietly radical: the affected arm is not fragile, and carefully dosed strength training, done under professional supervision with proper compression, may be one of the most effective tools available for taking back both the limb and the peace of mind that cancer treatment so often takes away.

Subject of Research: Resistance exercise and compression garment therapy for breast cancer-related lymphedema

Article Title: Effects of resistance exercise and compression garments in the management of breast cancer-related lymphedema: a randomized controlled trial

Article References: Zhu, M., Li, M., Li, J., Wu, P., Qiang, W., & Wang, Y. (2026). Effects of resistance exercise and compression garments in the management of breast cancer-related lymphedema: a randomized controlled trial. Holistic Integrative Oncology, 5(1), Article 25. https://doi.org/10.1007/s44178-026-00231-6

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00231-6

Keywords: breast cancer, lymphedema, resistance exercise, compression garments, randomized controlled trial, cancer rehabilitation, arm circumference, anxiety, quality of life, complex decongestive therapy, cancer survivorship, exercise oncology

The study, conducted by Scott Siegel of City of Hope Atlanta along with Karina Szymulanska-Ramamurthy and Digant Gupta of City of Hope Chicago, set out to fill a striking gap in the literature. Although integrative medicine is increasingly woven into oncology care, and the World Health Organization defines it as an interdisciplinary, evidence-based approach combining biomedical and complementary practices, virtually no published research has evaluated the impact of spinal manipulation and chiropractic care on functional outcomes in cancer patients. A literature search by the team found no prior studies analyzing outcomes on the Patient-Specific Functional Scale, a validated instrument that tracks activities each patient personally identifies as difficult, in this population. The researchers hypothesized that oncology patients receiving chiropractic care would show improvements in both function and pain intensity between a baseline visit and two subsequent follow-up visits.

Technically, the investigation took the form of a single-arm retrospective observational study, a chart review of 97 adult oncology patients treated within the Integrative Medicine Department at City of Hope Cancer Center Atlanta in Newnan, Georgia, during a 12-month window from June 1, 2024, to June 1, 2025. To be included, patients needed a documented cancer diagnosis, musculoskeletal complaints appropriate for chiropractic intervention, and Patient-Specific Functional Scale and pain intensity scores recorded before treatment at baseline and at the next two eligible visits. The exclusion criteria were extensive and clinically meticulous: patients were removed from consideration if they received only one chiropractic visit, lacked eligible follow-up within three months, or were undergoing concurrent interventions such as physical therapy, massage, acupuncture, orthopedic surgery, pain medication, or recent corticosteroid injections that could confound results. Manual chiropractic care was also ruled out where contraindicated, including in cases of severe osteoporosis, extremely low platelet counts, acute compression fracture, recent surgery, vertebral artery stenosis, blood clots, or cauda equina syndrome. Charts were additionally screened for indwelling devices and osseous metastases identified on imaging.

The intervention itself was deliberately adapted for oncology. Rather than traditional high-velocity, low-amplitude spinal manipulation, which could pose risks given cancer-related structural vulnerabilities, clinicians delivered low-force or instrument-assisted spinal and extremity manipulation, myofascial techniques, flexion-distraction, therapeutic exercise instruction, ergonomic advice, and counseling on activities of daily living. Each treatment plan was individualized and delivered by a licensed chiropractor embedded in the oncology clinic, reflecting the growing recognition that comprehensive cancer centers must offer a wide range of services to address the interrelated physical needs of their patients.

The measurement strategy centered on two patient-reported tools with established reliability, validity, and responsiveness in musculoskeletal and rehabilitation populations. The Patient-Specific Functional Scale asks patients to name an activity they find difficult and then rate their ability to perform it from 0, meaning unable to perform, to 10, meaning able to perform at their prior level. In this study, one patient-selected activity was tracked per patient across three ordered visits. Pain intensity was captured on an 11-point numerical rating scale from 0, no pain, to 10, worst pain. Importantly, the authors emphasize that the first and second follow-up visits, labeled FU1 and FU2, represent visit order rather than standardized elapsed-time points, because clinical scheduling was not protocolized. The mean interval from baseline to FU1 was 18.3 days, while the mean interval from baseline to FU2 was 37.5 days, with wide individual variation.

The statistical analysis was appropriately sophisticated for repeated-measures data. Linear mixed-effects models were used to account for within-subject correlation across the three visits, with visit as a categorical fixed effect and subject as a random intercept. Pairwise comparisons between baseline, FU1, and FU2 were adjusted using the Holm-Bonferroni method, and clinically meaningful change was evaluated through responder analyses using a minimal clinically important difference of at least 2.0 points for both outcomes. The models were further extended with interaction terms to test whether patterns of change differed by gender or race.

The results were statistically striking. Mean Patient-Specific Functional Scale scores rose from 4.45 at baseline to 5.13 at FU1 and 5.53 at FU2, while mean pain intensity fell from 6.07 at baseline to 5.10 at FU1 and 4.64 at FU2. All pairwise comparisons were significant at adjusted p values below 0.001. For function, the mean difference from baseline to FU2 was 1.077 points, and for pain the baseline-to-FU2 difference was 1.423 points. Clinically meaningful improvement, defined as at least a 2-point change, was achieved by 13.4 percent of patients for function and 22.7 percent for pain at FU1, rising to 26.8 percent and 44.3 percent respectively at FU2. The cohort had a mean age of 57.4 years, was predominantly female, and breast cancer was the most common diagnosis category.

Equally notable was the consistency of the response across demographic subgroups. Both males and females showed comparable patterns of functional gain and pain reduction, and the visit-by-gender interactions were not statistically significant for either outcome. Similarly, White and African American patients demonstrated parallel improvements, with no significant visit-by-race interactions, suggesting that the observed benefits did not diverge across these key patient characteristics. The authors argue that this consistency across subgroups supports the robustness of the observed patterns, even though the study could not establish causation.

The clinical implications are considerable. If the findings hold up under more rigorous testing, modified chiropractic care could become a nonpharmacological option for managing the musculoskeletal symptom burden of cancer treatment, potentially improving mobility, daily functioning, and quality of life alongside standard medical management. The authors stress that careful patient selection and coordination with the oncology care team remain essential for safety and appropriateness, particularly given the structural and hematologic vulnerabilities many cancer patients carry. This caution is well founded: the retrospective, single-arm, pre-post design without a concurrent control group means the improvements could reflect natural recovery, regression to the mean, expectations, or concurrent oncologic and supportive treatments such as analgesics, rehabilitation therapy, or palliative care, none of which could be fully controlled. The modest single-center sample, self-reported outcomes vulnerable to reporting bias, and heterogeneous follow-up intervals further limit the strength of any causal claim.

Nevertheless, the study has real strengths. It employed repeated, patient-centered outcome measures capturing both function and pain, evaluated clinically meaningful thresholds in addition to statistical significance, used two follow-up measurements rather than a single post-intervention assessment, and applied analytical methods that account for within-subject correlation. The authors are clear about the path forward: a properly powered prospective randomized trial with an appropriate comparison group, standardized assessment windows, documentation of co-interventions, and evaluation of the durability of changes, followed by multicenter studies to assess generalizability across oncology settings and cancer types. Mixed-methods and pragmatic research could further illuminate patient experience, optimal treatment frequency, and how such services might be implemented within comprehensive cancer care pathways. For now, the study stands as a provocative first quantification of functional improvement in cancer patients receiving chiropractic care, and a signal that one of the most common forms of complementary medicine may deserve a rigorously tested place in modern supportive oncology.

Subject of Research: Chiropractic care and functional outcomes in cancer patients

Article Title: Functional outcomes in oncology patients receiving chiropractic care: a retrospective chart review

Article References: Siegel, S., Szymulanska-Ramamurthy, K., & Gupta, D. (2026). Functional outcomes in oncology patients receiving chiropractic care: a retrospective chart review. Supportive Care in Cancer, 34(10), Article 1011. https://doi.org/10.1007/s00520-026-11248-y

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11248-y

Keywords: chiropractic care, oncology, cancer rehabilitation, pain management, musculoskeletal disorders, integrative medicine, supportive care, patient-specific functional scale, cancer survivors, retrospective study, spinal manipulation, quality of life